Cosmo Pharmaceuticals Announces Private Placement of Treasury Shares
Rhea-AI Summary
Cosmo Pharmaceuticals (OTC:CMOPF) completed a private placement of 937,086 treasury shares to Capital Group's SMALLCAP World Fund on February 3, 2026, representing ~5.3% of outstanding shares. The sale used existing treasury shares and therefore does not dilute existing shareholders; shares are fungible and rank pari passu. Cosmo said the transaction strengthens its shareholder base, enhances financial flexibility, and supports investment in MedTech AI, dermatology, gastroenterology, and CDMO. Cosmo will file required major shareholding notifications with SIX Swiss Exchange.
Positive
- Placement of 937,086 treasury shares (~5.3% outstanding)
- Transaction executed using treasury shares, causing no dilution
- Shares placed with Capital Group's SMALLCAP World Fund
- Company says placement strengthens shareholder base and financial flexibility
- Shares are fully fungible and rank pari passu
Negative
- Single institutional investor now holds ~5.3%—increases ownership concentration
- Major shareholding notifications required—short-term regulatory disclosure obligation
Dublin, Ireland--(Newsfile Corp. - February 3, 2026) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the successful completion of a private placement of 937,086 treasury shares. The shares were placed with Capital Group’s SMALLCAP World Fund.
The placement is equivalent to approximately
This investment represents one of the most significant institutional placements in Cosmo’s recent history and marks a major milestone in the Company’s ongoing transformation into a focused, innovation driven healthcare leader.
The transaction further strengthens Cosmo’s shareholder base, enhances financial flexibility, and supports continued investment behind the Company’s strategic growth priorities across MedTech AI, dermatology, gastroenterology, and CDMO.
Giovanni Di Napoli, Chief Executive Officer of Cosmo Pharmaceuticals, commented: “We see this transaction as an important step in accelerating our journey and delivering long term value for all shareholders. The investment was enabled by the progress we have made, the clarity of our Vision 2030 strategy, and our ambition to build a global healthcare innovation company at the intersection of therapeutics, digital platforms, and AI enabled MedTech.”
Svetlana Sigalova, Chief Financial Officer of Cosmo Pharmaceuticals, added: “This transaction reflects a highly strategic and disciplined use of treasury shares. It reinforces the strength of our financial position and supports our long-term capital allocation priorities as we continue to invest behind innovation, growth, and strategic execution.”
The transaction was conducted as a private placement with a single institutional investor. The shares are fully fungible with existing listed shares and rank pari passu in all respects. In accordance with applicable regulations, Cosmo will be filing the relevant major shareholding notifications with SIX Swiss Exchange.
About Cosmo
Cosmo is a life sciences company focused on MedTech AI, dermatology, gastrointestinal diseases, and contract development and manufacturing (CDMO). We design, develop, and manufacture advanced solutions that address critical medical needs and raise the standard of care. Our technologies are trusted by leading global pharmaceutical and MedTech companies and reach patients and healthcare providers around the world. Guided by our purpose - Building Health Confidence - our mission is to empower patients, healthcare professionals, and partners by innovating at the intersection of science and technology. Founded in 1997, Cosmo is headquartered in Dublin, Ireland, with offices in San Diego (USA), and in Lainate, Rome, and Catania (Italy). For more information, visit www.cosmohealthconfidence.com
Financial calendar
| 2025 FY results, Annual Report and ESG Report Annual General Meeting of Shareholders 2026 TP ICAP Conference, Paris | March 9, 2026 April 10, 2026 May 6-7, 2026 |
For further information, please contact:
This press release contains forward-looking statements that reflect Cosmo’s current expectations regarding the clinical development, regulatory assessment, and potential future availability of the investigational product. Such statements are subject to significant known and unknown risks and uncertainties, which may cause actual results, performance or achievements to differ materially from those expressed or implied herein. These risks and uncertainties include, without limitation, the completion and outcomes of additional clinical analyses, interactions with and determinations by regulatory authorities, reliance on third-party partners, the potential impact of external scientific or medical developments, and other factors described in the Cosmo’s publicly available filings and reports. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. The reader is cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Cosmo, and Cosmo assumes no obligation and disclaims any intent to update any such forward-looking statements, except as required by applicable law.
Attachments
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282487
FAQ
What exactly did Cosmo Pharmaceuticals announce on February 3, 2026 regarding CMOPF shares?
Who bought the Cosmo treasury shares in the CMOPF private placement?
Does the CMOPF private placement dilute existing shareholders?
What investor notifications will Cosmo file after the CMOPF private placement?
How does Cosmo say the CMOPF placement affects its strategy and financial position?
